Ohio Musculoskeletal and Neurological Institute, Ohio University, Athens, OH 45701, USA.
J Neurol. 2012 Jul;259(7):1326-30. doi: 10.1007/s00415-011-6349-6. Epub 2012 Jan 10.
Mal de debarquement syndrome (MdDS) is a disorder of phantom perception of self-motion of unknown cause. The purpose of this work was to describe the quality of life (QOL) of patients with MdDS and to estimate the economic costs associated with this disorder. A modified version of a QOL survey used for another neurological disease (multiple sclerosis; MSQOL-54) was used to assess the impact of MdDS on QOL in 101 patients. The estimated economic costs were based on self-reported direct and indirect costs of individuals living in the United States using Medicare reimbursement payment rates for 2011 in 79 patients. Patients with MdDS reported a poor overall QOL as indicated by a mean composite QOL score of 59.26 ± 1.89 (out of 100). The subcategories having the lowest QOL rating were role limitations due to physical problems (18.32 ± 3.20), energy (34.24 ± 1.47), and emotional problems (36.30 ± 4.00). The overall physical health composite score including balance was 49.40 ± 1.69, and the overall mental health composite score was 52.40 ± 1.83. The cost to obtain a diagnosis was $2,997 ± 337, which included requiring an average of 19 physician visits per patient. The direct cost of MdDS medical care was $826 ± 140 per patient per year, which mainly included diagnostic imaging and physician visits. The indirect costs (i.e., lost wages) were $9,781 ± 2,347 per patient per year. Among 65 patients who were gainfully employed when they acquired MdDS, the indirect costs were $11,888 ± 2,786 per patient per year. Thus, the total annual cost of the disorder ranged from $11,493 ± 2,341 to $13,561 ± 2,778 per patient per year depending on employment status prior to developing MdDS. MdDS negatively and dramatically impacts QOL, and also imposes a substantial economic burden on MdDS patients. These findings underscore the need for further basic and clinical research on MdDS.
晕动病(MdDS)是一种不明原因的自我运动幻觉障碍。本研究旨在描述 MdDS 患者的生活质量(QOL),并估计与该疾病相关的经济成本。使用另一种神经系统疾病(多发性硬化症;MSQOL-54)的 QOL 调查的改良版,评估了 101 名 MdDS 患者的 QOL 影响。在 79 名患者中,根据美国个人报告的直接和间接成本,使用 2011 年医疗保险报销支付率来估算经济成本。MdDS 患者报告整体生活质量较差,综合 QOL 评分为 59.26 ± 1.89(满分 100)。生活质量最低的亚类是因身体问题导致的角色受限(18.32 ± 3.20)、精力(34.24 ± 1.47)和情绪问题(36.30 ± 4.00)。包括平衡在内的整体身体健康综合评分得分为 49.40 ± 1.69,整体心理健康综合评分为 52.40 ± 1.83。获得诊断的费用为 2997 ± 337 美元,包括每位患者平均需要 19 次就诊。每位患者每年的 MdDS 医疗费用直接成本为 826 ± 140 美元,主要包括诊断性影像学检查和就诊费用。间接成本(即工资损失)为每位患者每年 9781 ± 2347 美元。在 65 名发病时就业的患者中,间接成本为每位患者每年 11888 ± 2786 美元。因此,根据发病前的就业状况,该疾病每年的总费用范围为每位患者 11493 ± 2341 至 13561 ± 2778 美元。MdDS 对 QOL 有负面影响且影响较大,也给 MdDS 患者带来了巨大的经济负担。这些发现强调了进一步开展 MdDS 基础和临床研究的必要性。